Thomas Frenzel

Summary

Affiliation: Bayer HealthCare AG
Country: Germany

Publications

  1. ncbi Comparative studies on the efficacy of MRI contrast agents in MRA
    Hanns Joachim Weinmann
    Research Laboratories, Schering AG, Berlin, Germany
    Acad Radiol 9:S135-6. 2002
  2. doi Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand
    Martin A Sieber
    Research Diagnostic Imaging Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 27:955-62. 2008
  3. doi Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C
    Thomas Frenzel
    Bayer Schering Pharma, Berlin, Germany
    Invest Radiol 43:817-28. 2008
  4. doi Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 30:374-83. 2009
  5. doi Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    TRG Diagnostic Imaging, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 44:226-33. 2009
  6. doi Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    Bayer Schering Pharma AG Contrast, Media Research, Muellerstrasse 178, 13353, Berlin, Germany
    Eur Radiol 19:1417-24. 2009
  7. doi The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 46:48-56. 2011
  8. pmc Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents: Comparison of Linear and Macrocyclic Agents
    Gregor Jost
    From the MR and CT Contrast Media Research, Bayer Healthcare Institute of Vegetative Physiology, Charité and Clinical Project Management, Bayer HealthCare, Berlin, Germany
    Invest Radiol 51:83-9. 2016
  9. doi Contrast Media for X-ray and Magnetic Resonance Imaging: Development, Current Status and Future Perspectives
    Thomas Frenzel
    From the MR and CT Contrast Media Research, Bayer Healthcare AG Department of Physical and Theoretical Chemistry, Free University Department of Radiology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin and Clinical Project Management General Medicine, Bayer HealthCare AG, Berlin, Germany
    Invest Radiol 50:671-8. 2015
  10. ncbi A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media
    Martin A Sieber
    Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 43:65-75. 2008

Collaborators

Detail Information

Publications11

  1. ncbi Comparative studies on the efficacy of MRI contrast agents in MRA
    Hanns Joachim Weinmann
    Research Laboratories, Schering AG, Berlin, Germany
    Acad Radiol 9:S135-6. 2002
  2. doi Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand
    Martin A Sieber
    Research Diagnostic Imaging Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 27:955-62. 2008
    ..Using a dosing regimen to simulate the exposure seen in patients with severe renal impairment, we investigated the effect of excess ligand on Gd-deposition and the depletion of endogenous ions...
  3. doi Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C
    Thomas Frenzel
    Bayer Schering Pharma, Berlin, Germany
    Invest Radiol 43:817-28. 2008
    ..Assessment of the complex stability and Gd3+ dissociation rate of all marketed gadolinium-based MRI contrast agents (GBCA) in human serum at pH 7.4 and 37 degrees C...
  4. doi Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    J Magn Reson Imaging 30:374-83. 2009
    ..The depletion of endogenous Zinc ions (Zn) caused by the administration of gadolinium-based contrast agents (GBCAs) has been suggested as a possible pathomechanism for nephrogenic systemic fibrosis (NSF)...
  5. doi Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    TRG Diagnostic Imaging, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 44:226-33. 2009
    ..The aim of this study was to determine the impact of a prolonged circulation time of GBCAs caused by reduced renal clearance on the long-term retention of Gd in the skin of rats after administration of different GBCAs...
  6. doi Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents
    Hubertus Pietsch
    Bayer Schering Pharma AG Contrast, Media Research, Muellerstrasse 178, 13353, Berlin, Germany
    Eur Radiol 19:1417-24. 2009
    ..In summary, we observed a correlation between the complex stability of GBCAs and the amount of residual Gd in the skin up to a year after application of GBCAs...
  7. doi The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats
    Hubertus Pietsch
    Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 46:48-56. 2011
    ..In addition, we evaluated whether an acute response to Gd exposure can initiate a process that results in fibrosis of the skin...
  8. pmc Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents: Comparison of Linear and Macrocyclic Agents
    Gregor Jost
    From the MR and CT Contrast Media Research, Bayer Healthcare Institute of Vegetative Physiology, Charité and Clinical Project Management, Bayer HealthCare, Berlin, Germany
    Invest Radiol 51:83-9. 2016
    ..In a second part of the study, cerebrospinal fluid (CSF) spaces were evaluated for contrast enhancement by fluid-attenuated magnetic resonance imaging (MRI)...
  9. doi Contrast Media for X-ray and Magnetic Resonance Imaging: Development, Current Status and Future Perspectives
    Thomas Frenzel
    From the MR and CT Contrast Media Research, Bayer Healthcare AG Department of Physical and Theoretical Chemistry, Free University Department of Radiology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin and Clinical Project Management General Medicine, Bayer HealthCare AG, Berlin, Germany
    Invest Radiol 50:671-8. 2015
    ..Nevertheless, diagnostic imaging will contribute significantly to the progresses in medicine, and new contrast media developments are mandatory to address the medical needs of the future. ..
  10. ncbi A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media
    Martin A Sieber
    Bayer Schering Pharma AG, Berlin, Germany
    Invest Radiol 43:65-75. 2008
    ....
  11. pmc 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives
    Jessica Lohrke
    MR and CT Contrast Media Research, Bayer HealthCare, Berlin, Germany
    Adv Ther 33:1-28. 2016
    ....